Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined Experimental and Simulation Studies Suggest a Revised Mode of Action of the Anti‐Alzheimer Disease Drug NQ‐Trp

14 Jul 2015

Abstract excerpt

Inhibition of the aggregation of the monomeric peptide β-amyloid (Aβ) into oligomers is a widely studied therapeutic approach in Alzheimer's disease (AD). Many small molecules have been reported to work in this way, including 1,4-naphthoquinon-2-yl-L-tryptophan (NQ-Trp). NQ-Trp has been reported to inhibit aggregation, to rescue cells from Aβ toxicity, and showed complete phenotypic recovery in an in vivo AD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Cholinesterase and Neurodegenerative Diseases
Share to Computational Drug Discovery Methods

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26179053
DOI: 10.1002/chem.201500888

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined Experimental and Simulation Studies Suggest a Revised Mode of Action of the Anti‐Alzheimer Disease Drug NQ‐TrpPMID 26179053Read ↗

Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor.Semantic proximity Read ↗

Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered ToxicitySemantic proximity Read ↗

A mechanistic model of tau amyloid aggregation based on direct observation of oligomers.Semantic proximity Read ↗

Targeting Amyloid Aggregation: An Overview of Strategies and MechanismsSemantic proximity Read ↗

Q-DOAS: A Proximity Quenching Assay for Real-Time Detection of Early Protein Aggregation EventsSemantic proximity Read ↗

Inhibitory effect of epigallocatechin-3-gallate as a potent anti-amyloidogenic agent against the G138E mutant of SOD1.Semantic proximity Read ↗

Dual-action peptide shuttles rescue Cu-amyloid-β-induced neurotoxicity and relocate Cu intracellularlySemantic proximity Read ↗

De novo designed protein inhibitors of amyloid aggregation and seedingSemantic proximity Read ↗

Modulating ALS-Related Amyloidogenic TDP-43307-319 Oligomeric Aggregates with Computationally Derived Therapeutic Molecules.Semantic proximity Read ↗

A novel small molecule screening platform for disrupting toxic tau oligomers in cellsSemantic proximity Read ↗

Hybrids of oxoisoaporphine–tetrahydroisoquinoline: novel multi-target inhibitors of inflammation and amyloid-β aggregation in Alzheimer’s diseaseSemantic proximity Read ↗

Structural stabilization of transthyretin by a new compound, 6-benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.